ARCT Q2 2025 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena

ARCTArcturus Therapeutics Holdings Inc.

$217M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M-46.7% YoY

Gross Profit

$25M100.0% margin

Operating Income

-$12M-47.4% margin

Net Income

-$9M-37.5% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-16.6%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$309M

Total Liabilities

$78M

Stockholders' Equity

$231M

Cash & Equivalents

$196M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$46M	-46.7%
Gross Profit	$25M	$46M	-46.7%
Operating Income	-$12M	-$21M	+45.0%
Net Income	-$9M	-$17M	+46.7%

Revenue Segments

Collaboration Revenue

$25M87%

Grant

$4M13%